As of late, it has definitely been a great time to be an investor in Array BioPharma Inc. ARRY. The stock has moved higher by 12.4% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path.
We certainly think that this might be the case, particularly if you consider ARRY’s recent earnings estimate revision activity. From this look, the company’s future is quite favorable; as ARRY has earned itself a Zacks Rank #2 (Buy), meaning that its recent run may continue for a bit longer, and that this isn’t the top for the in-focus company. You can see the complete list of today’s Zacks #1 Rank stocks here.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Array BioPharma Inc. (ARRY) : Free Stock Analysis Report
To read this article on Zacks.com click here.